Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Author Correction: Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

The Original Article was published on 20 January 2020

Correction to: Nature Immunology https://doi.org/10.1038/s41590-019-0578-8, published online 20 January 2020.

In the supplementary information originally posted for this article, Supplementary Fig. 1 included only a truncated form of the MC.7.G5 TCR chains used to express soluble protein in bacteria (in panel b). This sequence includes a truncated constant domain that contains some mutations from the native sequence. This is made clear in the updated Supplementary Fig. 1, and another panel has been added at the bottom of the figure that shows the protein sequence with the leader and full-length natural constant regions, including the transmembrane domain. It is recommended that researchers wishing to make versions of this TCR refer to the sequence deposited at GenBank (MN782533.2) and include a constant domain that suits their intended purpose.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Andrew K. Sewell.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Crowther, M.D., Dolton, G., Legut, M. et al. Author Correction: Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nat Immunol 21, 695 (2020). https://doi.org/10.1038/s41590-020-0640-6

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing